Horse blood 5% (Bradsure Biologicals, Loughborough, UK) and NAD (Sigma) 20 mg/L were added to support the growth of fastidious bacteria.
For anaerobic bacteria, Wilkins-Chalgren agar (Unipath) supplemented with 5% horse blood was used. All strains were tested at a final inoculum of 10 4 cfu and for a few selected strains at an increased inoculum of 10 6 cfu, using a multipoint inoculator (Denley Instruments, Billingshurst, UK). Plates were incubated at 35-37°C for 18-24 h in air; or for fastidious bacteria, in an atmosphere enriched with 4-6% CO 2 ; or for anaerobic bacteria in an anaerobic cabinet (Don Whitely, Shipley, UK) in an atmosphere of 10% hydrogen 10% CO 2 and 80% nitrogen.
The MIC was defined as the lowest antibiotic concentration at which no more than two colonies were observed. Amoxycillin and clavulanic acid were combined in a ratio of 2:1, and the results were recorded in terms of the amoxycillin MIC.
Tentative MIC and zone diameter breakpoints
MICs (as described above) and zone size diameter were measured for 646 recent isolates following BSAC recommendations (BSAC Newsletter, Summer, 1998). Briefly 6 mm diameter discs prepared in-house containing 1, 2 and 5 g gemifloxacin were placed on the appropriate medium seeded with an inoculum equivalent to semi-confluent growth and incubated (as above). The BSAC formula for breakpoint determination was applied 3 assuming C max 1.2 mg/L, elimination half life c. 8-10 h and protein binding as 60%. This gives a breakpoint of 0.5-1 mg/L. Scattergrams of zone size plotted against MIC were performed and false sensitivity and resistance rates estimated.
Results

Quality control
The MICs of all agents other than gemifloxacin for the reference strains were identical to, or within a two-fold dilution of, the reference values determined in this laboratory (data not shown).
Comparative in-vitro potency
The potency of gemifloxacin against the Enterobacteriaceae was similar to that of ciprofloxacin, trovafloxacin and levofloxacin, all compounds having MICs within one doubling dilution of each other (Table I) . The E. coli strains tested included 10 clinical isolates with a ciprofloxacin MIC of 1 mg/L. These strains showed cross-resistance (MIC 0.5 mg/L) to gemifloxacin. Against P. aeruginosa gemifloxacin displayed a similar degree of potency to ciprofloxacin and when individual strains were compared both these compounds were two-fold more potent than levofloxacin and trovafloxacin. There was a wide range of susceptibility of Stenotrophomonas maltophilia to all the fluoroquinolones with gemifloxacin and trovafloxacin being two-fold more potent than the other two fluoroquinolones.
Against methicillin-susceptible S. aureus (MSSA), gemifloxacin and trovafloxacin were markedly more potent than ciprofloxacin (a 32-fold difference) or levofloxacin (an eight-fold difference) and co-amoxiclav (an eight-fold difference). Methicillin-resistant strains of S. aureus were all less susceptible to the fluoroquinolones than were the MSSA; the most susceptible strain had a gemifloxacin MIC of 1 mg/L and a ciprofloxacin MIC of 16 mg/L.
Similar differences between the fluoroquinolones were observed when the methicillin-susceptible S. epidermidis strains were tested: gemifloxacin and trovafloxacin were markedly more potent than the other agents studied. Generally, methicillin-resistant strains of S. epidermidis were susceptible to the fluoroquinolones but two strains that had a gemifloxacin MIC of 2 mg/L were susceptible to 4 and 8 mg/L of trovafloxacin and 64 and 16 mg/L ciprofloxacin, respectively.
Gemifloxacin was the most potent agent (other than co-amoxiclav) studied against E. faecalis and E. faecium. Gemifloxacin was eight-to 16-fold more potent than ciprofloxacin and four-fold more potent than trovafloxacin; however, strains with reduced susceptibilities (gemifloxacin MIC 2 mg/L) were noted in both species.
Against streptococci (including S. pneumoniae) gemifloxacin was two-to four-fold more potent than trovafloxacin and 16-to 32-fold more potent than ciprofloxacin. A total of 16 fluoroquinolone-resistant S. pneumoniae (ciprofloxacin MIC 1 mg/L) isolates were studied and again gemifloxacin was the most potent agent of the class. There were 10 strains with ciprofloxacin MICs of 4-8 mg/L and these were susceptible to gemifloxacin 0.06-0.12 mg/L. Four strains had ciprofloxacin MICs of 128 mg/L and these were susceptible to gemifloxacin 0.5-2 mg/L.
The H. influenzae, Neisseria spp. and Moraxella catarrhalis strains tested were highly susceptible to all the fluoroquinolones and those strains known to producelactamase were as susceptible as the -lactamase-negative strains.
Among the anaerobic organisms studied, Clostridium perf r i n g e n s was highly susceptible to gemifloxacin, all strains being inhibited by 0.12 mg/L or less. Clostridium diffic i l e w a s less susceptible with gemifloxacin MICs of 2 mg/L or less. The anaerobic cocci were equally susceptible to gemifloxacin and trovafloxacin. Against B. fragilis, t r o v a flo x a c i n was marginally more potent or as potent as gemifloxacin, all strains being inhibited by 0.5 mg/L or less of the latter agent.
The susceptibility of 47 strains of both Gram-negative and Gram-positive organisms was studied at both the routine inoculum of 10 4 cfu per inoculum and at 10 6 cfu per inoculum (data not shown). Forty-two showed an MIC identical or within two-fold greater at the higher inoculum. The remainder showed a four-fold difference. 
Tentative MIC and zone diameter breakpoints
For the purpose of initial analysis a conservative MIC breakpoint (BP) of 0.5 mg/L was chosen for all strains. Data obtained for 2 g and 5 g gemifloxacin disc contents revealed that zones of inhibition ranged from 30 to 45 mm for the sensitive population for all genera except Pseudomonas (data not shown). Zones of this magnitude have been shown to cause unacceptable zone merging when multidisc testing is performed on a 90 mm Petri dish and therefore analysis was only executed on data for a 1 g disc content for all strains except Pseudomonas sp. (Figure 1 ). Using a zone diameter breakpoint (ZD BP) of 20 mm, three strains were falsely interpreted as sensitive and they comprised one E. coli (MIC of 1 mg/L, ZD 20 mm), one S. aureus (MIC 1 mg/L, ZD 32 mm) and one E. faecalis (MIC 2 mg/L, ZD 20 mm). With regard to false resistant reporting, 36 of the 603 strains tested (6%) were interpreted as falsely resistant; eight strains were enterococci with MICs close to the BP (MIC range 0.12-0.5 mg/L), 17 were strains of Enterobacteriaceae with reduced susceptibility to ciprofloxacin and higher gemifloxacin MICs than strains of the same genera with no demonstrated mechanism of resistance, and the remaining 11 organisms comprised Serratia, Acinetobacter, Providencia and Stenotrophomonas spp. with MICs close to the MIC BP. Figure 2 shows the results for Pseudomonas spp. tested using a 5 g disc content. Using a ZD BP of 20 mm no false resistance was recorded and only two strains with MICs close to the MIC BP were reported as falsely sensitive. Tentative recommendations for gemifloxacin are summarized in Table II .
Discussion
The data reported in this study are essentially similar (that is, within one doubling dilution) to that previously described 1,2 with the following important exceptions. Oh and colleagues 1 showed that 90% of MRSA were suscep- tible to 1 mg/L of gemifloxacin while we found the MIC 90 to be 8 mg/L. This difference could well reflect the fact that fluoroquinolone resistance in S. aureus has increased in recent years and differs from one locality to another. Comican and Jones 2 suggest that gemifloxacin is considerably less potent against B. fragilis (MIC 90 8 mg/L) as against 0.5 mg/L found with our data. Methodological differences might explain these observations and require to be resolved.
The activity of gemifloxacin against S. pneumoniae is particularly noteworthy. Against penicillin-susceptible and -resistant strains our data confirm those of Kelly et al., 5 in that the fluoroquinolone maintains activity against both groups. In addition, our data show that gemifloxacin is also active against those strains that are intermediately resistant to ciprofloxacin (MIC 2-16 mg/L). Gemifloxacin MICs are 0.06-0.12 mg/L, below the tentative breakpoint. The most resistant stain we studied had a ciprofloxacin MIC of 128 mg/L and was susceptible to 1 mg/L of gemifloxacin. Recent studies on the mechanisms of resistance of pneumococci, 6 particularly the substrate specificity of efflux pumps in this organism, may explain such differences in activity.
A tentative breakpoint of 0.5 mg/L was chosen which should readily distinguish between resistant and susceptible populations of common pathogens. It was interesting to note that strains of Enterobacteriaceae that have a presumed mechanism of resistance, such as a mutation in gyrA or parC (with an MIC of 0.5 mg/L) nevertheless were demonstrated as 'falsely' resistant by our methodologies. It is possible therefore that the disc testing system is more sensitive than agar dilution procedures in identifying this population. It is possible that a breakpoint of 0.5 mg/L is too conservative and that clinical trials may suggest that 1 mg/L will be more appropriate, but we believe a cautious approach is justifiable.
Gemifloxacin is a significant advance on currently marketed fluoroquinolones, especially in the potential treatment of chest infections, and certainly merits clinical study.
